As NF-κB modulators exhibited low toxic effects against normal astrocytes (which indicate their selectivity towards cancer cells), hence phytochemicals might play a role as potential agents in clinical trials, facilitating the finding of better therapy to treat GBM. Here, NFKB1 is linked to glioblastoma.